SG11201602012RA - Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof - Google Patents

Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof

Info

Publication number
SG11201602012RA
SG11201602012RA SG11201602012RA SG11201602012RA SG11201602012RA SG 11201602012R A SG11201602012R A SG 11201602012RA SG 11201602012R A SG11201602012R A SG 11201602012RA SG 11201602012R A SG11201602012R A SG 11201602012RA SG 11201602012R A SG11201602012R A SG 11201602012RA
Authority
SG
Singapore
Prior art keywords
formulations
compositions
maintaining
strength
performance
Prior art date
Application number
SG11201602012RA
Inventor
Nathaniel W Silver
Ying-Ja Chen
David A Berry
Michael J Hamill
Subhayu Basu
Luke Hamm
Alison Williams
David Erbe
Maltzahn Geoffrey Von
Original Assignee
Pronutria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronutria Inc filed Critical Pronutria Inc
Publication of SG11201602012RA publication Critical patent/SG11201602012RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • C12Y207/04003—Adenylate kinase (2.7.4.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
SG11201602012RA 2013-09-25 2014-09-25 Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof SG11201602012RA (en)

Applications Claiming Priority (30)

Application Number Priority Date Filing Date Title
US201361882211P 2013-09-25 2013-09-25
US201361882198P 2013-09-25 2013-09-25
US201361882260P 2013-09-25 2013-09-25
US201361882271P 2013-09-25 2013-09-25
US201361882189P 2013-09-25 2013-09-25
US201361882222P 2013-09-25 2013-09-25
US201361882214P 2013-09-25 2013-09-25
US201361882180P 2013-09-25 2013-09-25
US201361882250P 2013-09-25 2013-09-25
US201361882225P 2013-09-25 2013-09-25
US201361882129P 2013-09-25 2013-09-25
US201361882274P 2013-09-25 2013-09-25
US201361882254P 2013-09-25 2013-09-25
US201361882240P 2013-09-25 2013-09-25
US201361882219P 2013-09-25 2013-09-25
US201361882220P 2013-09-25 2013-09-25
US201361882300P 2013-09-25 2013-09-25
US201361882243P 2013-09-25 2013-09-25
US201361882267P 2013-09-25 2013-09-25
US201361882305P 2013-09-25 2013-09-25
US201361882295P 2013-09-25 2013-09-25
US201361882232P 2013-09-25 2013-09-25
US201361882246P 2013-09-25 2013-09-25
US201361882235P 2013-09-25 2013-09-25
US201361882234P 2013-09-25 2013-09-25
US201361882212P 2013-09-25 2013-09-25
US201361882229P 2013-09-25 2013-09-25
US201361882264P 2013-09-25 2013-09-25
US201361906862P 2013-11-20 2013-11-20
PCT/US2014/057537 WO2015048342A2 (en) 2013-09-25 2014-09-25 Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof

Publications (1)

Publication Number Publication Date
SG11201602012RA true SG11201602012RA (en) 2016-04-28

Family

ID=52744707

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201602012RA SG11201602012RA (en) 2013-09-25 2014-09-25 Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
SG11201601999UA SG11201601999UA (en) 2013-09-25 2014-09-25 Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601999UA SG11201601999UA (en) 2013-09-25 2014-09-25 Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control

Country Status (12)

Country Link
US (7) US20160219910A1 (en)
EP (5) EP3048900A2 (en)
JP (2) JP2016537402A (en)
KR (2) KR20160056941A (en)
CN (2) CN107223019A (en)
AU (3) AU2014324897A1 (en)
CA (3) CA2925521A1 (en)
IL (2) IL244668A0 (en)
MX (3) MX2016003943A (en)
RU (2) RU2016110800A (en)
SG (2) SG11201602012RA (en)
WO (8) WO2015048346A2 (en)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2975215T3 (en) * 2011-12-14 2024-07-04 Univ Arkansas Delivery of therapeutic agents via a collagen-binding protein
CN104364259A (en) 2012-03-26 2015-02-18 普罗努塔利亚公司 Nutritive fragments, proteins and methods
CN104470946A (en) 2012-03-26 2015-03-25 普罗努塔利亚公司 Charged nutritive proteins and methods
EP2831097A4 (en) * 2012-03-26 2016-01-20 Pronutria Inc NUTRIENT PROTEINS AND FRAGMENTS COMPRISING LITTLE OR NO PHENYLALANINE AND METHODS
JP2016533739A (en) 2013-07-29 2016-11-04 ダニスコ・ユーエス・インク Mutant enzyme
MX2016003943A (en) 2013-09-25 2016-12-09 Pronutria Biosciences Inc Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment.
US10570181B2 (en) * 2014-08-19 2020-02-25 The University Court Of The University Of Edinburgh Synthetic multiphase systems
CN107135653A (en) * 2014-10-01 2017-09-05 安迅生物制药公司 Colicine variant
MX2017006127A (en) 2014-11-11 2017-11-08 Clara Foods Co Methods and compositions for egg white protein production.
US9908064B2 (en) 2015-02-06 2018-03-06 Leidos, Inc. Portable fluidic platform for rapid cell-free production of protein biologics
WO2016196013A2 (en) * 2015-06-03 2016-12-08 AgBiome, Inc. Pesticidal genes and methods of use
WO2016205397A2 (en) * 2015-06-15 2016-12-22 Klibanov Alexander L Target-specific delivery of therapeutic agents
US10835593B2 (en) 2015-08-27 2020-11-17 The United States Of America As Represented By The Secretary Department Of Health And Human Services Modified anthrax toxin protective antigen
EP3390425B1 (en) 2015-12-16 2024-08-07 Diet4Life ApS Dietary peptides
WO2017142080A1 (en) * 2016-02-18 2017-08-24 天野エンザイム株式会社 Intestinal flora improvement agent
JP6820347B2 (en) 2016-03-01 2021-01-27 クラフト・フーズ・グループ・ブランズ・エルエルシー Pellet-like colorants containing chromoprotein complexes and foods containing them
US20190076521A1 (en) * 2016-03-03 2019-03-14 Hoyu Co., Ltd. Soybean allergy antigen
WO2018158985A1 (en) * 2017-03-03 2018-09-07 学校法人藤田学園 Allergy antigen and epitope thereof
JP7041923B2 (en) * 2016-03-03 2022-03-25 学校法人藤田学園 Soy allergy antigen
US20190071680A1 (en) * 2016-03-16 2019-03-07 Dsm Ip Assets B.V. Microbial production of nicotinic acid riboside
EP3462904B1 (en) * 2016-05-24 2024-12-18 Novozymes A/S Gastric stable polypeptides having alpha-galactosidase activity and polynucleotides encoding same
WO2017202966A1 (en) 2016-05-24 2017-11-30 Novozymes A/S Polypeptides having alpha-galactosidase activity and polynucleotides encoding same
CN109196098A (en) * 2016-05-24 2019-01-11 诺维信公司 Composition comprising the polypeptide with galactanase activity and the polypeptide with betagalactosidase activity
US11414464B2 (en) * 2016-07-22 2022-08-16 Evaxion Biotech A/S Chimeric proteins for inducing immunity towards infection with S. aureus
WO2018035046A1 (en) 2016-08-15 2018-02-22 President And Fellows Of Harvard College Treating infections using idsd from proteus mirabilis
US10548941B2 (en) * 2016-11-13 2020-02-04 Imagine Pharma Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
JOP20190146A1 (en) 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
CN110431234B (en) * 2017-01-18 2024-04-16 巴斯夫农业种子解决方案美国有限责任公司 BP005 toxin gene and methods of use thereof
WO2018148573A1 (en) 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
EP3592429A1 (en) 2017-03-06 2020-01-15 DuPont Nutrition Biosciences ApS Novel fungal fucosidases and their use in preventing and/or treating a pathogenic infection in an animal
MX387183B (en) 2017-03-15 2025-03-18 Int N&H Denmark Aps NOVEL TRYPSIN-LIKE SERINE PROTEASES AND THEIR USES.
WO2018169750A1 (en) 2017-03-15 2018-09-20 Danisco Us Inc Trypsin-like serine proteases and uses thereof
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
JP7052967B2 (en) * 2017-05-16 2022-04-12 東栄新薬株式会社 Method for measuring β-1,6-glucanase mutant and β-1,6-glucan
US11858974B2 (en) * 2017-05-22 2024-01-02 Resq Biotech Macrocyclic modulators of disease associated protein misfolding and aggregation
EP3651587A4 (en) * 2017-06-29 2020-11-11 International Dehydrated Foods, Inc. HIGH PROTEIN COMPOSITIONS AND PROCESS FOR THEIR PRODUCTION
MA49906A (en) 2017-08-14 2020-06-24 Axcella Health Inc BRANCHED-CHAIN AMINO ACIDS FOR THE TREATMENT OF LIVER DISEASE
KR101961560B1 (en) * 2017-09-22 2019-03-22 김성은 Composition for improving, prevention or treatment of muscular atrophy comprising Solanum tuberosum L. extract
US11377484B2 (en) * 2017-10-02 2022-07-05 Vib Vzw Compounds to inhibit bacterial s-layer protein assembly
US11273138B2 (en) * 2017-11-02 2022-03-15 Bioventures, Llc Use of amino acid supplementation for improved muscle protein synthesis
CN107927797A (en) * 2017-12-11 2018-04-20 重庆市生物技术研究所有限责任公司 It is a kind of to eat the wholefood formula containing small peptide for muscle decay syndrome crowd
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
BR112020009765A2 (en) * 2017-12-20 2020-11-03 Société des Produits Nestlé S.A. compositions and methods that use a combination of autophagy inducer and high protein content for inducing autophagy
WO2019121855A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
CA3083276A1 (en) 2017-12-22 2019-06-27 Pioneer Hi-Bred International, Inc. Combinations of insecticidal polypeptides having improved activity spectrum and uses thereof
CN108559739B (en) * 2018-05-11 2021-03-26 中国农业科学院北京畜牧兽医研究所 Mannanase PMan5A mutants with improved thermotolerance and their genes and applications
KR102061735B1 (en) 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) A vaccine composition comprising recombinant protein of attenuated staphylococcal enterotoxin and cytotoxin
MA52971A (en) 2018-06-20 2021-04-28 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN THE MUSCLE
JP2021529735A (en) 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． Method for producing amino acid composition
MX2020013731A (en) 2018-06-20 2021-02-26 Axcella Health Inc Compositions for therapy and health containing amino acids with bitter taste.
CU20200106A7 (en) 2018-06-20 2021-08-06 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS
MX2021000102A (en) * 2018-07-03 2021-05-31 Leidos Inc Materials and methods for cell-free expression of vaccine epitope concatemers.
CA3106895A1 (en) * 2018-07-20 2020-01-23 Mend Nutrition Inc. Nutritional compositions for enhancement of muscle performance
TWI680139B (en) * 2018-07-21 2019-12-21 東海大學 Use of short peptides and compositions thereof for treating / preventing diabetes and related diseases
US11965003B2 (en) * 2018-08-31 2024-04-23 Unichem Laboratories Ltd Recombinant lectin variants
CN109337816A (en) * 2018-09-29 2019-02-15 昆明理工大学 A method for reducing total nitrogen, total phosphorus and COD in molasses alcohol waste mash
WO2020070009A1 (en) * 2018-10-02 2020-04-09 Novozymes A/S Endonuclease 1 ribonucleases for cleaning
US11860139B2 (en) * 2018-10-08 2024-01-02 Applied Photophysics Limited System and method for analysing the composition of a quenched flow reaction liquid
EP3877519A4 (en) 2018-11-09 2022-08-24 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF MOGROSIDES
US12162816B2 (en) 2018-12-18 2024-12-10 Johnson Matthey Public Limited Company Method of reducing aromatic nitro compounds
WO2020142786A1 (en) 2019-01-06 2020-07-09 Katlinskaya Yuliya Microbially derived peptides and proteins for immunotherapy
CN109628485B (en) * 2019-02-02 2020-09-22 中国科学院植物研究所 Application of OsDBP1 protein in regulating cold tolerance of rice
CN109938245B (en) * 2019-04-04 2022-03-18 贵州大学 A physical method for reducing N-glycolylneuraminic acid in red meat
US20220183322A1 (en) * 2019-04-05 2022-06-16 Novozymes A/S Redox enzymes in animal feed compositions
US20220227820A1 (en) * 2019-04-25 2022-07-21 University Of Florida Research Foundation, Incorporated Recombinant glycan binding proteins
US20200359652A1 (en) * 2019-05-17 2020-11-19 Agri-King, Inc. Bacterial strain compositions and methods of using same
US11312754B2 (en) 2019-05-31 2022-04-26 Access Business Group International Llc Sunflower seed protein-derived peptides
US12317914B2 (en) 2019-06-07 2025-06-03 Societe Des Produits Nestle S.A. Compositions and methods using one or more autophagy-inducing amino acids to potentiate musculoskeletal effect of one or more anabolic amino acids
WO2020254664A1 (en) * 2019-06-20 2020-12-24 Société des Produits Nestlé S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids
US20220242946A1 (en) * 2019-06-26 2022-08-04 The Johns Hopkins University Methods and materials for targeted expansion of regulatory t cells
CN110344077A (en) * 2019-07-01 2019-10-18 吉林大学 A method of by l-cysteine electrochemistry formated n-acetyl-L-cysteine
GB201909563D0 (en) 2019-07-03 2019-08-14 British American Tobacco Investments Ltd Method
MX2022000374A (en) 2019-07-11 2022-03-25 Clara Foods Co PROTEIN COMPOSITIONS AND CONSUMABLE PRODUCTS THEREOF.
US12096784B2 (en) 2019-07-11 2024-09-24 Clara Foods Co. Protein compositions and consumable products thereof
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes
MX2022002834A (en) 2019-09-16 2022-04-06 Novozymes As POLYPEPTIDES WITH BETA-GLUCANASE ACTIVITY AND POLYNUCLEOTIDES THAT ENCODE THEM.
CN110713529B (en) * 2019-11-14 2022-04-01 中国农业科学院郑州果树研究所 Application of VvDUF642 gene in causing abortion of plant seeds
CA3160106A1 (en) * 2019-11-25 2021-06-03 The Regents Of The University Of California Antigenic neuron specific enolase peptides for diagnosing and treating autism
EP4090678A4 (en) * 2020-01-10 2024-01-10 Intron Biotechnology, Inc. A method for preparing porcine myoglobin using escherichia coli
TW202134267A (en) 2020-01-24 2021-09-16 美商格爾托公司 Animal-free dietary collagen
TR202002698A2 (en) * 2020-02-21 2021-09-21 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Nutritional compositions for cancer patients undergoing chemotherapy and/or radiotherapy and/or pre-post surgery
US20230114818A1 (en) * 2020-03-31 2023-04-13 Amano Enzyme Inc. Collagenase agent and use thereof
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
EP4142510A1 (en) * 2020-04-30 2023-03-08 Grandes Vinos y Viñedos SA Wine lees, derivatives thereof and their uses
CN113717264B (en) * 2020-05-20 2023-08-25 中国科学院遗传与发育生物学研究所 Soybean RNA binding protein GmTSN990 related to lipid metabolism regulation and encoding gene and application thereof
CN111704651B (en) * 2020-07-27 2021-10-08 南京安吉生物科技有限公司 Polypeptide RV3 and RV4 with anti-aging effect and application thereof
TWI784298B (en) * 2020-08-06 2022-11-21 大江生醫股份有限公司 Use of bioactive compound for preparing a composition promoting skin collagen production and enhancing skin collagen density
KR20230091911A (en) * 2020-09-28 2023-06-23 얀센 파마슈티칼즈, 인코포레이티드 Variant Staphylococcus aureus LukA and LukB Polypeptides and Vaccine Compositions
JP7762657B2 (en) * 2020-09-28 2025-10-30 テルモ株式会社 Composition containing hyaluronic acid or its salt and indigo carmine
FR3114744B1 (en) * 2020-10-02 2024-01-05 Basf Beauty Care Solutions France Sas New use of a peptide to improve the comfort of the skin and/or mucous membranes and/or the appearance of skin appendages
WO2022120423A1 (en) * 2020-12-08 2022-06-16 James Cook University Peptides and uses thereof
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
NZ804057A (en) * 2021-03-04 2025-07-25 Helix Nanotechnologies Inc Compositions including sbi adjuvants and methods of use thereof
CN113121641B (en) * 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 A class of multifunctional polypeptides and their applications in the field of medicine
CA3214495A1 (en) * 2021-03-25 2022-09-29 Bio-Cat, Inc. Fungal protease mixtures and uses thereof
AU2022254722A1 (en) 2021-04-07 2023-11-23 Ingenious Ingredients, LP 1-methylxanthine-based bioactive composition and method of use thereof
WO2022221420A2 (en) * 2021-04-13 2022-10-20 Capsida, Inc. Selected aav compositions having preferred brain enrichment
CN113189318B (en) * 2021-04-26 2022-05-10 杭州凯莱谱精准医疗检测技术有限公司 Method for quantitative determination of trace elements in milk
CN115947791A (en) * 2021-05-11 2023-04-11 博格隆(浙江)生物技术有限公司 Preparation method of recombinant Protein A Protein and affinity chromatography medium
US20240317816A1 (en) * 2021-06-04 2024-09-26 Genevive, Inc. Peptides for immunotherapy
AU2022316976A1 (en) * 2021-07-27 2024-02-29 Px Ing, Llc Bioactive compositions and methods of use thereof
CN113584005B (en) * 2021-08-27 2024-03-01 江南大学 Preparation of aminopeptidase and application of aminopeptidase in protein debittering
WO2023041435A1 (en) * 2021-09-14 2023-03-23 Syngulon S.A. Bacteriocin for applications against mycobacterium
CN114062571B (en) * 2021-11-15 2022-08-02 厦门大学 Method for detecting mycotoxin in aquaculture water
CN118974074A (en) * 2022-03-01 2024-11-15 赢创运营有限公司 Production of collagen and bacterial collagen-like proteins by recombinant microbial biotechnology
WO2023168396A2 (en) * 2022-03-04 2023-09-07 Cella Farms Inc. Computational system and algorithm for selecting nutritional microorganisms based on in silico protein quality determination
AU2023272468A1 (en) 2022-05-14 2024-11-14 Novonesis Plant Biosolutions A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
CN116536288A (en) * 2022-07-25 2023-08-04 河北农业大学 Enzyme preparation composition and application thereof in preparation of haw juice
EP4587565A1 (en) * 2022-09-15 2025-07-23 Novozymes A/S Fungal signal peptides
EP4594485A1 (en) * 2022-09-29 2025-08-06 Shiru, Inc. Naturally occurring decarboxylase proteins with superior gelation properties for preparing foods and cosmetics
EP4599073A2 (en) * 2022-10-07 2025-08-13 Mercury Bio, Inc. Methods for actively loading therapeutic molecules into modified extracellular vesicles for targeted delivery to cells
CN115850514A (en) * 2022-10-26 2023-03-28 山东迅达康兽药有限公司 Recombinant chicken interferon alpha protein, preparation method and application thereof
CN115558692B (en) * 2022-12-06 2023-04-28 蓝鲲海洋生物科技(烟台)有限公司 Method for preparing tuna peptide rich in anserine and glutathione
CN115990152B (en) * 2022-12-09 2024-12-24 上海市第十人民医院 Use of branched-chain amino acids in diagnosis and treatment of neuropathic pain in diabetes
CN116310717B (en) * 2023-02-14 2025-06-20 长沙理工大学 Target student network model training method and low-resolution image recognition method
IL322837A (en) * 2023-03-09 2025-10-01 BioNTech SE Peptidoglycan hydrolases with bactericidal activity
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
WO2024213599A1 (en) * 2023-04-12 2024-10-17 Dsm Ip Assets B.V. Glucoamylase as binding agent for non-animal protein food products
WO2024220717A1 (en) * 2023-04-20 2024-10-24 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
WO2024253228A1 (en) * 2023-06-09 2024-12-12 주식회사 메타파인즈 Composition for preventing or treating cachexia and muscle loss
CN116790701B (en) * 2023-07-21 2024-02-20 广东海洋大学 A tilapia skin polypeptide and its preparation method and application in preparing anti-muscle atrophy products
CN117264016B (en) * 2023-09-11 2024-08-16 温州肯恩大学(Wenzhou-KeanUniversity) Anti-inflammatory polypeptide and synthesis method thereof
WO2025080765A1 (en) * 2023-10-12 2025-04-17 Rutgers, The State University Of New Jersey Methods to deliver exogenous protein/peptide cargo to cell cytosol and uses thereof
CN117115754B (en) * 2023-10-23 2023-12-26 贵州省种畜禽种质测定中心 Intelligent duck shed monitoring method based on computer vision
CN118307633B (en) * 2023-11-24 2025-02-18 中国水产科学研究院黄海水产研究所 Antarctic krill ACE (angiotensin converting enzyme) inhibitory peptide LGGIF, YLGGAL, LGGLNQ and application thereof
EP4574163A1 (en) * 2023-12-22 2025-06-25 Université Paris Cité Antihyperglycemic compounds and methods
WO2025155915A1 (en) * 2024-01-17 2025-07-24 Anagram Therapeutics, Inc. Methods and compositions for treating congenital sucrase-isomaltase deficiency
CN118542864B (en) * 2024-07-26 2024-11-26 广东海洋大学 A carnosine composition for alleviating atherosclerosis and its application
CN120718979A (en) * 2025-08-14 2025-09-30 中国科学院天津工业生物技术研究所 An in vitro biotransformation synthesis system for trehalose 6-phosphate and its application

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870801A (en) 1968-08-09 1975-03-11 Lever Brothers Ltd Fluid aqueous protein compositions and food products prepared therefrom
US3736150A (en) * 1971-08-04 1973-05-29 Kellog Co Beverage containing egg albumen and amino acid
JPS585672B2 (en) 1975-01-16 1983-02-01 フシセイユ カブシキガイシヤ Teifenylalanine plastein
US4230695A (en) * 1976-08-02 1980-10-28 Vitose Corporation Enhanced protein assimilation with fructose
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4687782A (en) 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
JPH0665280B2 (en) 1987-03-04 1994-08-24 味の素株式会社 Protein gelling agent and protein gelling method using the same
DE68905387T2 (en) 1988-06-22 1993-10-21 Ajinomoto Kk Amino acid food compositions.
AU4244793A (en) 1992-05-12 1993-12-13 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Human cell cycle checkpoint genes
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
DE4442668C2 (en) 1994-11-30 1997-09-18 Milupa Ag Process for the preparation of a phenylalanine-free infant and toddler food
AU4413096A (en) 1994-12-02 1996-06-19 Indiana University Foundation Phenylalanine free proteins
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
US6537792B1 (en) * 1996-07-24 2003-03-25 Iowa State University Protein engineering of glucoamylase to increase pH optimum, substrate specificity and thermostability
US6800726B1 (en) 1996-11-01 2004-10-05 Pioneer Hi-Bred International, Inc. Proteins with increased levels of essential amino acids
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
CA2274414A1 (en) * 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
US6630320B1 (en) 2000-05-08 2003-10-07 Devisco Foods International, Inc. Treatment of hypertension in mammals with hydrolyzed whey proteins
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20060159724A1 (en) 2000-08-08 2006-07-20 Bell Stacey J Nutritional supplement for the management of weight
US6592863B2 (en) 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
EP1375664B1 (en) 2001-03-30 2009-11-04 Ajinomoto Co., Inc. Method for the secretion and production of protein
GB0110288D0 (en) 2001-04-26 2001-06-20 Novartis Nutrition Ag Composition and treatment method
EP1472282B1 (en) 2002-01-16 2009-12-09 Milkhaus Laboratory, Inc. Use of calmodulin to promote bone regeneration
US20040266689A1 (en) 2002-01-16 2004-12-30 Mcmichael John Use of calmodulin to promote bone regeneration
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
DE60216523T2 (en) 2002-06-19 2007-10-04 Centro de Investigacion en Alimentacion y Desarrollo, A.C., Hermosillo PREPARATION AND USE OF SOY PROTEIN HYDROLYSATES ENRICHED WITH BRANCHED AMINO ACIDS
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US7273738B2 (en) 2002-10-01 2007-09-25 Novozymes A/S Family GH-61 polypeptides
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US9288998B2 (en) 2002-11-06 2016-03-22 Medwell Foods, Inc. Edible nutritive composite
JP4970694B2 (en) 2002-12-02 2012-07-11 株式会社明治 Persistent muscle fatigue improver
CA2507987C (en) 2002-12-06 2013-01-29 Sunstar Inc. A vegetable composition having blood enhancing properties
US6814983B2 (en) 2002-12-10 2004-11-09 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
EP2272864A3 (en) 2002-12-20 2011-02-16 Amgen Inc. Binding agents which inhibit myostatin
US6812249B2 (en) 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050089546A1 (en) * 2003-09-16 2005-04-28 Dick Wurtman Compositions and methods comprising complex carbohydrate and alpha-lactalbumin
US20060150283A1 (en) 2004-02-13 2006-07-06 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
KR20060127857A (en) * 2003-10-29 2006-12-13 알투스 파마슈티컬스 인코포레이티드 Non-pancreatic protease for plasma cholesterol level control and pain treatment
EP1685764A1 (en) * 2005-01-27 2006-08-02 Globus Egg Sciences B.V. Anti-hypertensive functional food products
US20110183052A1 (en) 2004-10-07 2011-07-28 Next Proteins, Inc. Protein beverage and method of making the same
WO2006047308A2 (en) 2004-10-21 2006-05-04 Iowa State University Research Foundation, Inc. Novel vegetable protein fractionization process and compositions
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
FR2882896B1 (en) 2005-03-14 2007-05-04 Larena Sa FOOD COMPOSITION FOR PREVENTING FRAGILITY SYNDROME IN OLDER PEOPLE
CA2861310A1 (en) 2005-03-15 2006-09-28 Bp Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
WO2006105112A2 (en) 2005-03-29 2006-10-05 Ajinomoto Co., Inc. Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
US20060280840A1 (en) 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
US8551544B2 (en) 2005-07-13 2013-10-08 Archer Daniels Midland Company Protein isolate compositions and uses thereof
WO2007023172A2 (en) * 2005-08-23 2007-03-01 Armand Herberger Protein composition for treating a physiologically caused, clinically normal increased need for protein
JP5161779B2 (en) 2005-09-21 2013-03-13 バーコン ニュートラサイエンス （エムビー） コーポレイション Preparation of canola protein isolate containing isoelectric precipitation
CN101494970B (en) 2005-09-28 2012-09-26 文特里亚生物科学公司 Oral formulations for bowel disorders and/or hydration
RU2383209C2 (en) 2005-10-26 2010-03-10 Хилл'С Пет Ньютришн, Инк. Composition and methods for increase of nonfat muscle bulk and/or reduction of fat growth
RU2008121259A (en) 2005-10-28 2009-12-10 Нестек С.А. (Ch) FOOD CONTAINING A BRANCHED AMINO ACID AND METHOD OF TREATMENT WITH ITS USE
US8329646B2 (en) 2005-11-30 2012-12-11 Nestec S.A. Methods for the treatment of muscle loss
CN101501207B (en) 2005-12-06 2014-03-12 合成基因组股份有限公司 Synthetic genomes
CA2643136C (en) 2005-12-23 2017-04-18 J. Craig Venter Institute, Inc. Installation of genomes or partial genomes into cells or cell-like systems
US20090304901A1 (en) 2006-01-25 2009-12-10 Steven Craig Bobzin Modulating plant protein levels
EP1993378A4 (en) 2006-03-01 2010-03-17 Gen Mills Marketing Inc Post-freezing acidification of frozen dairy products
CN102690833B (en) 2006-03-07 2015-09-09 巴斯夫酶有限责任公司 Zymohexase, encode their nucleic acid and preparation and their method of use
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
MX2009006782A (en) 2006-12-21 2009-09-21 Verenium Corp Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them.
US20080206430A1 (en) 2007-02-22 2008-08-28 Rafael Avila Compositions consisting of blended vegetarian proteins
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
WO2008135960A2 (en) 2007-05-04 2008-11-13 Bopa Ireland Limited A composition for increasing stamina
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
CA2691691C (en) 2007-06-20 2013-09-24 Seth J. Baum Compositions and methods of treating chronic kidney disease
EP2036978A1 (en) 2007-09-14 2009-03-18 URSAPHARM Arzneimittel GmbH & Co. KG Recombinant preparation of selected bromelain fractions
WO2009076481A1 (en) 2007-12-10 2009-06-18 Healthspan Solutions, Llc Determination of tissue-specific profile of amino acid requirements form the relationship between the amounts of trnas for individual amino acids and the protein-bound amino acid profile of the tissue
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
US20090203606A1 (en) 2008-02-05 2009-08-13 Wolfe Robert R Systems for and Methods of use of Therapeutic Nutrition for the Management of Age-Associated and Age-Specific Health Conditions of the Elderly
CA2649477C (en) 2008-04-18 2016-04-19 Nuvocare Health Sciences Inc. Composition and method for promoting internal health and external appearance
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
US20100055246A1 (en) 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods
CA2805888C (en) 2008-10-17 2016-08-16 Nestec S.A. Whey protein compostions, methods and uses
US20100179089A1 (en) 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
BRPI0923993A2 (en) 2009-03-12 2016-01-26 Ind Nutrigrains S A De C V hybrid vegetable protein and method for obtaining a hybrid vegetable protein
US20120178672A1 (en) 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010126353A1 (en) 2009-04-27 2010-11-04 N.V. Nutricia Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding
EP2258208A1 (en) * 2009-06-02 2010-12-08 University of Limerick Protein Product With Modified Antigenicity
CN102481338A (en) 2009-06-12 2012-05-30 威斯康星校友研究基金会 Glycomacropeptide Medicinal Food for Nutritional Control of Phenylketonuria and Other Metabolic Diseases
NO2448424T3 (en) 2009-06-30 2018-04-07
WO2011027188A1 (en) 2009-09-02 2011-03-10 Team Foods Colombia S.A. Composition with high protein content for the food industry
KR100930537B1 (en) 2009-09-03 2009-12-09 주식회사 블루콤 Micro speaker with high power diaphragm mating structure
CA2779161A1 (en) 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
CN101715964A (en) 2009-12-10 2010-06-02 刘建敏 Diet supplementary formula and method of nutrition supplementary food for moderate type II diabetes rehabilitation
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
CA2786307A1 (en) 2010-01-06 2011-07-14 Cargill, Incorporated High protein cooked product
WO2011093693A1 (en) 2010-01-29 2011-08-04 N.V. Nutricia Liquid enteral nutritional composition suitable for tube feeding, minimizing lower and upper tract digestive conditions
CN102933598A (en) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 Novel glucagon analogues
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
US9486003B2 (en) 2010-06-28 2016-11-08 Nestec S.A. Hypocaloric, high protein nutritional compositions and methods of using same
CN101886107A (en) 2010-07-02 2010-11-17 广东海洋大学 A method for enzymatically preparing high F-value oligopeptides from Pinctada martensii
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
WO2012015303A1 (en) 2010-07-28 2012-02-02 Unifine Food & Bake Ingredients B.V. Glazing agent for baked goods
US20130217614A1 (en) 2010-08-18 2013-08-22 Burcon Nutrascience (Mb) Corp Production of protein solutions from soy
WO2012024611A1 (en) * 2010-08-20 2012-02-23 Natural Alternatives International, Inc. Methods of treating sarcopenia and frailty
WO2012081971A1 (en) * 2010-12-17 2012-06-21 N.V. Nutricia Whey protein composition with a reduced astringency
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
US11235008B2 (en) * 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
PH12013501927A1 (en) * 2011-04-18 2013-10-14 Nestec Sa Nutritional compositions comprising alpha-hydroxyisocaproic acid
US20120288588A1 (en) * 2011-05-12 2012-11-15 Jon Barron Functional cereal formulation
FR2978647B1 (en) 2011-08-01 2013-08-16 Groupe Lactalis FUNCTIONAL AND STABLE PROTEIN MIXTURE FOR FOOD COMPOSITIONS INTENDED FOR PEOPLE REQUIRING IMPROVEMENT AND MAINTAINMENT OF THEIR PHYSICAL CONDITION.
WO2013028547A1 (en) 2011-08-19 2013-02-28 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
US8609446B2 (en) 2011-10-06 2013-12-17 Tsmc Solid State Lighting Ltd. Method and apparatus for accurate die-to-wafer bonding
TW201330845A (en) 2011-10-18 2013-08-01 Ajinomoto Kk Therapeutic agent for pancreatic cancer and/or biliary tract cancer
US9364463B2 (en) 2011-11-18 2016-06-14 Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
KR102203056B1 (en) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 Differentiation of human embryonic stem cells into single hormonal insulin positive cells
WO2013095793A1 (en) 2011-12-22 2013-06-27 Aveo Pharmaceuticals, Inc. Identification of multigene biomarkers
JP6145778B2 (en) 2012-02-06 2017-06-14 Ｅａファーマ株式会社 Preventive or therapeutic agent for idiopathic inflammatory myopathy
AU2013202942B2 (en) * 2012-03-09 2016-05-12 Fonterra Co-Operative Group Limited Uses of casein compositions
CN104364259A (en) 2012-03-26 2015-02-18 普罗努塔利亚公司 Nutritive fragments, proteins and methods
US20150232520A1 (en) 2012-03-26 2015-08-20 Pronutria, Inc. Charged Nutritive Fragments, Proteins and Methods
US9605040B2 (en) 2012-03-26 2017-03-28 Axcella Health Inc. Nutritive proteins and methods
CN104470946A (en) 2012-03-26 2015-03-25 普罗努塔利亚公司 Charged nutritive proteins and methods
EP2831097A4 (en) * 2012-03-26 2016-01-20 Pronutria Inc NUTRIENT PROTEINS AND FRAGMENTS COMPRISING LITTLE OR NO PHENYLALANINE AND METHODS
JP2015519878A (en) 2012-03-26 2015-07-16 プロニュートリア・インコーポレイテッドＰｒｏｎｕｔｒｉａ， Ｉｎｃ． Nutritional fragments, proteins, and methods
EP2841590A4 (en) * 2012-04-27 2016-03-23 Pronutria Inc NUCLEIC ACIDS, CELLS AND METHODS FOR PRODUCING SECRETED PROTEINS
DK2879523T3 (en) 2012-07-31 2017-01-16 Nestec Sa NUTRITIONAL COMPOSITION FOR THE PROMOTION OF MUSCULOSKELETAL HEALTH OF PATIENTS WITH INFLAMMATORY GAS (IBD)
US20150307562A1 (en) * 2012-11-20 2015-10-29 Pronutria Biosciences, Inc. Engineered secreted proteins and methods
WO2014134225A2 (en) * 2013-02-26 2014-09-04 Pronutria, Inc. Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance
EP3027181A1 (en) 2013-07-31 2016-06-08 Leeds Beckett University Dietary supplement
US20160228506A1 (en) 2013-09-25 2016-08-11 Pronutria, Inc. Compositions and Formulations for Prevention and Reduction of Tumorigenesis, Cancer Cell Proliferation and Invasion, and Methods of Production and Use Thereof in Cancer Treatment
MX2016003943A (en) 2013-09-25 2016-12-09 Pronutria Biosciences Inc Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment.

Also Published As

Publication number Publication date
WO2015048346A4 (en) 2015-11-05
SG11201601999UA (en) 2016-04-28
WO2015048340A4 (en) 2015-11-26
MX2016003944A (en) 2016-12-09
US11357824B2 (en) 2022-06-14
MX2016003945A (en) 2016-12-09
US20200188481A1 (en) 2020-06-18
EP3048905A2 (en) 2016-08-03
WO2015048345A4 (en) 2015-10-15
WO2015048340A2 (en) 2015-04-02
WO2015048348A2 (en) 2015-04-02
US20160354436A1 (en) 2016-12-08
EP3076991A2 (en) 2016-10-12
EP3048900A2 (en) 2016-08-03
CN107223019A (en) 2017-09-29
AU2014324901A1 (en) 2016-05-19
WO2015048346A3 (en) 2015-09-17
AU2014324900A1 (en) 2016-05-19
KR20160058940A (en) 2016-05-25
WO2015048345A2 (en) 2015-04-02
US20160317614A1 (en) 2016-11-03
CN107223020A (en) 2017-09-29
WO2015048333A2 (en) 2015-04-02
JP2016537302A (en) 2016-12-01
WO2015048340A3 (en) 2015-10-08
WO2015048342A2 (en) 2015-04-02
JP2016537402A (en) 2016-12-01
MX2016003943A (en) 2016-12-09
WO2015048342A8 (en) 2015-08-27
EP3054793A2 (en) 2016-08-17
CA2925450A1 (en) 2015-04-02
AU2014324897A1 (en) 2016-05-19
CA2925521A1 (en) 2015-04-02
WO2015048332A2 (en) 2015-04-02
WO2015048345A3 (en) 2015-09-17
IL244668A0 (en) 2016-04-21
WO2015048334A2 (en) 2015-04-02
US9878004B2 (en) 2018-01-30
WO2015048333A4 (en) 2015-10-15
IL244697A0 (en) 2016-04-21
KR20160056941A (en) 2016-05-20
WO2015048346A2 (en) 2015-04-02
WO2015048334A3 (en) 2015-10-15
US10463711B2 (en) 2019-11-05
WO2015048348A3 (en) 2015-10-08
US20160339078A1 (en) 2016-11-24
WO2015048332A3 (en) 2015-08-27
CA2925557A1 (en) 2015-04-02
RU2016110842A (en) 2017-10-30
WO2015048342A3 (en) 2015-08-06
US20160219910A1 (en) 2016-08-04
US20160228503A1 (en) 2016-08-11
EP3048904A2 (en) 2016-08-03
US20200306342A1 (en) 2020-10-01
WO2015048333A3 (en) 2015-08-13
RU2016110800A (en) 2017-10-30
WO2015048332A4 (en) 2015-10-29
WO2015048348A4 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
IL244697A0 (en) Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
IL267758B (en) Seed-origin endophyte populations, compositions, and methods of use
IL245184B (en) Prostacyclin compounds, compositions and methods of use thereof
HUE048666T2 (en) Agricultural endophyte-plant compositions, and methods of use
ZA201506682B (en) Compositions and methods for the improved production and delivery of rna
IL246252A0 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SG11201502264SA (en) Stable metal compounds, their compositions and methods of their use
ZA201403268B (en) Novel compositions, preparation thereof and use thereof for production of cast polyamides
PL2981600T3 (en) Formulations, use as dishwashing compositions and their production
IL239840A0 (en) Polymyxins, compositions, methods of making and methods of use
PL2988764T3 (en) Anti-dandruff compositions, and methods of use thereof
IL235262A0 (en) Polymorph compositions, methods of making, and uses thereof
IL244066A0 (en) Triazolopyridine compounds, compositions and methods of use thereof
PT3038656T (en) Compound of glycosaminoglycan, preparation method and use thereof
ZA201308268B (en) Herbicidal composition comprising pinoxaden and fluroxypyrester, and methods of use thereof
EP2766375A4 (en) Preparation of novel fluorocompounds, methods of preparation and compositions made therefrom
PL2998311T3 (en) Mixture of alkylglycosides, manufacture and use thereof
PL3019024T3 (en) Compositions and methods for enhancing exercise performance
SG11201505891VA (en) Catalyst compositions and methods of making and using same
EP2967055A4 (en) Biocide compositions, methods of manufacture, and methods of use
IL236568A0 (en) Alkylthiophene-rich compositions, uses thereof and methods of manufacturing the same
EP3003319A4 (en) Method of increasing muscle mass and strength and compositions therefor
SG11201405376TA (en) CRYSTALLINE FORMS OF 5α-ANDROSTANE-3β, 5, 6β-TRIOL AND PREPARATION METHODS THEREOF
EP2945703A4 (en) Formulations of albu-bche, preparation and uses thereof
EP3057972A4 (en) Novel compositions, uses and methods for their preparation